Compare ADMA Biologics Inc (ADMA) vs Avalanche Treasury Corporation Class A Common Stock (AVAT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ADMA Biologics Inc vs Avalanche Treasury Corporation Class A Common Stock — how do they compare? ADMA Biologics Inc trades at $9.87 (market cap $2.22B), while Avalanche Treasury Corporation Class A Common Stock trades at $0.37 (market cap $15.33M). The key difference: ADMA Biologics Inc is far larger — about 144.8× Avalanche Treasury Corporation Class A Common Stock's market cap, and ADMA Biologics Inc is trading nearer its 52-week high, Avalanche Treasury Corporation Class A Common Stock nearer its low. Which is the better fit depends on your goals.
| ADMA | AVAT | |
|---|---|---|
Market Cap | $2.22B | $15.33M |
Sector | Health | Financials |
52-Week High | $20.38 | $10.75 |
52-Week Low | $7.60 | $0.30 |
Enterprise Value | $2.29B | $15.33M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.87, up 1.23% today, with a bullish technical signal supported by moving averages. The company reported strong 2025 fundamentals, including $510.17M revenue, 32.98% net income margin, and robust profitability metrics like 41.9% ROE. However, recent Q1 and Q2 2026 earnings missed expectations, and the stock faces significant negative sentiment due to multiple class-action lawsuits alleging securities fraud, with deadlines in August 2026.
The outlook is mixed: strong fundamentals and an 88.89% analyst buy rating support upside, but legal overhangs and earnings misses pose near-term risks. Investors should weigh solid financial health against potential volatility from litigation outcomes and execution consistency.
AVAT trades at $0.37, up 9.83% in the past 24 hours. The stock shows a bearish technical signal with negative cash flow from operations of -$930,710 in 2025, though net income is positive at $8.28 million. Recent news highlights its Nasdaq listing as an operating company focused on capital allocation.
The outlook is cautious due to weak operational cash flow and bearish technical indicators. Investment appeal hinges on improved profitability and cash generation. Key risks include execution challenges and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About Avalanche Treasury Corporation Class A Common Stock
Avalanche Treasury Corp operates as a digital asset treasury company focused on holding and managing digital asset investments. The company was founded on September 22, 2025, and is headquartered in New York, NY.
Read more on AVAT →
